These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 25593015)

  • 21. Outcome of recurrent and metastatic head and neck squamous cell cancer patients after first line platinum and cetuximab therapy.
    Siano M; Infante G; Resteghini C; Cau MC; Alfieri S; Bergamini C; Granata R; Miceli R; Locati L; Licitra L; Bossi P
    Oral Oncol; 2017 Jun; 69():33-37. PubMed ID: 28559018
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A randomized, phase 2 trial of docetaxel with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic head and neck squamous cell cancer.
    Jimeno A; Bauman JE; Weissman C; Adkins D; Schnadig I; Beauregard P; Bowles DW; Spira A; Levy B; Seetharamu N; Hausman D; Walker L; Rudin CM; Shirai K
    Oral Oncol; 2015 Apr; 51(4):383-8. PubMed ID: 25593016
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Cetuximab in head and neck squamous cell carcinoma: a systematic review and Meta-analysis].
    Song Q; Li X; Li B
    Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2015 Jan; 29(1):67-75. PubMed ID: 25966559
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase II trial of sorafenib in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or nasopharyngeal carcinoma.
    Elser C; Siu LL; Winquist E; Agulnik M; Pond GR; Chin SF; Francis P; Cheiken R; Elting J; McNabola A; Wilkie D; Petrenciuc O; Chen EX
    J Clin Oncol; 2007 Aug; 25(24):3766-73. PubMed ID: 17704426
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase II study of cetuximab in combination with docetaxel in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck after platinum-containing therapy: a multicenter study of the Arbeitsgemeinschaft Internistische Onkologie.
    Knoedler M; Gauler TC; Gruenwald V; Matzdorff A; Schroeder M; Dietz A; Jordan WO; Arnold D; Hennemann B; Hofele C; Weissinger F; Eberhardt W; Keilholz U
    Oncology; 2013; 84(5):284-9. PubMed ID: 23445718
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase II clinical and exploratory biomarker study of dacomitinib in patients with recurrent and/or metastatic squamous cell carcinoma of head and neck.
    Kim HS; Kwon HJ; Jung I; Yun MR; Ahn MJ; Kang BW; Sun JM; Kim SB; Yoon DH; Park KU; Lee SH; Koh YW; Kim SH; Choi EC; Koo DH; Sohn JH; Kim B; Kwon NJ; Yun HJ; Lee MG; Lee JH; Kim TM; Kim HR; Kim JH; Paik S; Cho BC
    Clin Cancer Res; 2015 Feb; 21(3):544-52. PubMed ID: 25424851
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Palbociclib and cetuximab compared with placebo and cetuximab in platinum-resistant, cetuximab-naïve, human papillomavirus-unrelated recurrent or metastatic head and neck squamous cell carcinoma: A double-blind, randomized, phase 2 trial.
    Adkins DR; Lin JC; Sacco A; Ley J; Oppelt P; Vanchenko V; Komashko N; Yen CJ; Wise-Draper T; Lopez-Picazo Gonzalez J; Radulovic S; Shen Q; Thurm H; Martini JF; Hoffman J; Huang X; Melichar B; Tahara M
    Oral Oncol; 2021 Apr; 115():105192. PubMed ID: 33571736
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase II evaluation of sorafenib in advanced and metastatic squamous cell carcinoma of the head and neck: Southwest Oncology Group Study S0420.
    Williamson SK; Moon J; Huang CH; Guaglianone PP; LeBlanc M; Wolf GT; Urba SG
    J Clin Oncol; 2010 Jul; 28(20):3330-5. PubMed ID: 20498388
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A randomized phase II study of cetuximab every 2 weeks at either 500 or 750 mg/m2 for patients with recurrent or metastatic head and neck squamous cell cancer.
    Fury MG; Sherman E; Lisa D; Agarwal N; Algazy K; Brockstein B; Langer C; Lim D; Mehra R; Rajan SK; Korte S; Lipson B; Yunus F; Tanvetyanon T; Smith-Marrone S; Ng K; Xiao H; Haque S; Pfister DG
    J Natl Compr Canc Netw; 2012 Nov; 10(11):1391-8. PubMed ID: 23138167
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy.
    Vermorken JB; Trigo J; Hitt R; Koralewski P; Diaz-Rubio E; Rolland F; Knecht R; Amellal N; Schueler A; Baselga J
    J Clin Oncol; 2007 Jun; 25(16):2171-7. PubMed ID: 17538161
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A randomized phase II study comparing the efficacy and safety of the glyco-optimized anti-EGFR antibody tomuzotuximab against cetuximab in patients with recurrent and/or metastatic squamous cell cancer of the head and neck - the RESGEX study.
    Klinghammer K; Fayette J; Kawecki A; Dietz A; Schafhausen P; Folprecht G; Rottey S; Debourdeau P; Lavernia J; Jacobs A; Ahrens-Fath I; Dietrich B; Baumeister H; Zurlo A; Ochsenreither S; Keilholz U
    ESMO Open; 2021 Oct; 6(5):100242. PubMed ID: 34482179
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Randomized Phase II Trial of Ficlatuzumab With or Without Cetuximab in Pan-Refractory, Recurrent/Metastatic Head and Neck Cancer.
    Bauman JE; Saba NF; Roe D; Bauman JR; Kaczmar J; Bhatia A; Muzaffar J; Julian R; Wang S; Bearelly S; Baker A; Steuer C; Giri A; Burtness B; Centuori S; Caulin C; Klein R; Saboda K; Obara S; Chung CH
    J Clin Oncol; 2023 Aug; 41(22):3851-3862. PubMed ID: 36977289
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Docetaxel, cisplatin, and fluorouracil for patients with inoperable recurrent or metastatic head and neck squamous cell carcinoma.
    Cho H; Nishiike S; Yamamoto Y; Takenaka Y; Nakahara S; Yasui T; Hanamoto A; Inohara H
    Auris Nasus Larynx; 2015 Oct; 42(5):396-400. PubMed ID: 25721854
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A randomized phase 2 study of temsirolimus and cetuximab versus temsirolimus alone in recurrent/metastatic, cetuximab-resistant head and neck cancer: The MAESTRO study.
    Seiwert TY; Kochanny S; Wood K; Worden FP; Adkins D; Wade JL; Sleckman BG; Anderson D; Brisson RJ; Karrison T; Stadler WM; Vokes EE
    Cancer; 2020 Jul; 126(14):3237-3243. PubMed ID: 32365226
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Methotrexate plus or minus cetuximab as first-line treatment in a recurrent or metastatic (R/M) squamous cell carcinoma population of the head and neck (SCCHN), unfit for cisplatin combination treatment, a phase Ib-randomized phase II study Commence.
    Ham JC; van Meerten E; Fiets WE; Beerepoot LV; Jeurissen FJF; Slingerland M; Jonker MA; Husson O; van der Graaf WTA; van Herpen CML
    Head Neck; 2020 May; 42(5):828-838. PubMed ID: 31903657
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study.
    Bauml J; Seiwert TY; Pfister DG; Worden F; Liu SV; Gilbert J; Saba NF; Weiss J; Wirth L; Sukari A; Kang H; Gibson MK; Massarelli E; Powell S; Meister A; Shu X; Cheng JD; Haddad R
    J Clin Oncol; 2017 May; 35(14):1542-1549. PubMed ID: 28328302
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety and feasibility of every-other-week maintenance cetuximab after first-line chemotherapy in patients with recurrent or metastatic head and neck squamous cell cancer.
    Bossi P; Kornek G; Lanzetta G; Rozzi A; Füreder T; Locati L; Licitra L
    Head Neck; 2013 Oct; 35(10):1471-4. PubMed ID: 23042567
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase II study of vinorelbine/cetuximab in patients with recurrent/metastatic squamous cell carcinoma of the head and neck progressing after at least two chemotherapy regimens.
    Massa E; Dessì M; Gaspardini G; Saba F; Cherchi V; Mantovani G
    Oral Oncol; 2010 Nov; 46(11):818-21. PubMed ID: 20920877
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Subgroup Analysis According to Human Papillomavirus Status and Tumor Site of a Randomized Phase II Trial Comparing Cetuximab and Cisplatin Combined With Radiation Therapy for Locally Advanced Head and Neck Cancer.
    Buglione M; Maddalo M; Corvò R; Pirtoli L; Paiar F; Lastrucci L; Stefanacci M; Belgioia L; Crociani M; Vecchio S; Bonomo P; Bertocci S; Borghetti P; Pasinetti N; Triggiani L; Costa L; Tonoli S; Grisanti S; Magrini SM
    Int J Radiat Oncol Biol Phys; 2017 Mar; 97(3):462-472. PubMed ID: 27986347
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A prospective randomized phase II study comparing metronomic chemotherapy with chemotherapy (single agent cisplatin), in patients with metastatic, relapsed or inoperable squamous cell carcinoma of head and neck.
    Patil VM; Noronha V; Joshi A; Muddu VK; Dhumal S; Bhosale B; Arya S; Juvekar S; Banavali S; D'Cruz A; Bhattacharjee A; Prabhash K
    Oral Oncol; 2015 Mar; 51(3):279-86. PubMed ID: 25578869
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.